

Role of Dopamine D₂ Receptors for Antipsychotic Activity

Nathalie Ginovart and Shitij Kapur

Contents

1	Introduction	28
1.1	Role of Dopamine in the Pathophysiology of Schizophrenia	29
2	Mechanism of Antipsychotic Action	31
2.1	Antipsychotic Treatment	31
2.2	Role of D ₂ Receptor Blockade	33
3	Mechanisms Underlying Speed and Onset of Antipsychotic Response	39
4	Linking Dopaminergic Disturbances, Psychology and Pharmacology in Schizophrenia ..	40
5	Conclusion and Future Directions	41
	References	42

Abstract This review summarizes the current state of knowledge regarding the proposed mechanisms by which antipsychotic agents reduce the symptoms of schizophrenia while giving rise to adverse side effects. The first part summarizes the contribution of neuroimaging studies to our understanding of the neurochemical substrates of schizophrenia, putting emphasis on direct evidence suggestive of a presynaptic rather than a postsynaptic dysregulation of dopaminergic neurotransmission in this disorder. The second part addresses the role of D₂ and non-D₂ receptor blockade in the treatment of schizophrenia and highlights a preponderant role of D₂ receptors in the mechanism of antipsychotic action. Neuroimaging studies have defined a narrow, but optimal, therapeutic window of 65–78 %

N. Ginovart

Department of Psychiatry, Unité de Neuroimagerie, University of Geneva, Hôpital Belle Idée,
Chemin du Petit Bel-Air, 2, Geneva CH-1225, Switzerland
e-mail: nathalie.ginovart@unige.ch

S. Kapur (✉)

Department of Psychological Medicine, Institute of Psychiatry, King's College London,
De Crespigny Park, PO Box 053, London SE5 8AF, UK
e-mail: Shitij.Kapur@iop.kcl.ac.uk

D₂ receptor blockade within which most antipsychotics achieve optimal clinical efficacy with minimal side effects. Some antipsychotics though do not conform to that therapeutic window, notably clozapine. The reasons for its unexcelled clinical efficacy despite subthreshold levels of D₂ blockade are unclear and current theories on clozapine's mechanisms of action are discussed, including transiency of its D₂ receptor blocking effects or preferential blockade of limbic D₂ receptors. Evidence is also highlighted to consider the use of extended antipsychotic dosing to achieve transiency of D₂ blockade as a way to optimize functional outcomes in patients. We also present some critical clinical considerations regarding the mechanisms linking dopamine disturbance to the expression of psychosis and its blockade to the progressive resolution of psychosis, keeping in perspective the speed and onset of antipsychotic action. Finally, we discuss potential novel therapeutic strategies for schizophrenia.

Keywords Schizophrenia • Antipsychotic drugs • Dopamine receptor • D₂ blockade • PET imaging

1 Introduction

Schizophrenia is a chronic and disabling disease afflicting nearly 1 % of the general population (Perala et al. 2007). Clinically, the disorder manifests with a large variety of symptoms that fall into three categories: positive, negative, and cognitive (Kapur and Mamo 2003; Lieberman et al. 2005). Positive symptoms typically reflect a distortion of normal functions that are regarded as manifestations of psychosis and include hallucinations, delusions, and disorganized thoughts. Negative symptoms are associated with a diminution or loss of normal emotions and behaviors and manifest as affective blunting, social isolation, poverty of speech, anhedonia, and avolition. Cognitive symptoms relate to abnormal thought processes and manifest as deficits in attention, working memory, and executive functioning. Schizophrenia appears to be a polygenic disorder in which genetic factors combined with abnormalities in early brain development (including apoptosis, synaptic pruning, and disruption of neuronal migration) may confer a constitutional vulnerability to the disease (Walker et al. 2004). Subsequent environmental insults (including exposure to infectious, toxic, or traumatic insults and stress in utero or during childhood) may unmask this vulnerability and trigger overt manifestation of schizophrenia (Tsuang 2000). Within this framework, dysregulations of the dopamine (DA) neurotransmitter system have been most intimately associated with the pathophysiology of schizophrenia. Moreover, all antipsychotics act by blocking DA receptors, indicating that opposing DA signaling is central for alleviating psychotic symptoms. It is this aspect of the illness that is the focus of this review, with special attention given to the DA D₂ receptors.

1.1 Role of Dopamine in the Pathophysiology of Schizophrenia

For almost 50 years, schizophrenia research has focused on dopaminergic signaling as a key feature in the treatment and etiology of the disease. In particular, the original “DA hypothesis” posits a hyperdopaminergic function in brain as a possible cause of the illness (van Rossum 1966). This hypothesis was initially based on several lines of indirect evidence. First, exposure to psychostimulants such as amphetamine, which increase brain DA activity, can induce psychotic symptoms in normal individuals and worsen psychotic symptoms in schizophrenia patients (Connell 1958), whereas drugs known as DA depleters, such as reserpine, alleviate them (Carlsson et al. 1957). Further evidence for a DA hyperfunction in schizophrenia came from research on the mechanism of antipsychotic action. Notably, early work from Carlsson and Lindqvist (1963) indicated that central DA receptor blockade by chlorpromazine and haloperidol was the mechanism of their antipsychotic action. Actually, all antipsychotics act by blocking DA D₂ receptors and there is a tight correlation between the clinical potency of these drugs and their pharmacological potency at blocking D₂ receptors (Seeman and Lee 1975). This observation leads to the dominant theory that the positive symptoms of the illness are directly related to a subcortical dopaminergic overactivity, which may be due to an excess of DA itself or to hypersensitive D₂ receptors.

1.1.1 Dopamine Receptor Studies in Schizophrenia

Since all current antipsychotics block D₂ receptors, there has been tremendous interest in whether the expression of those receptors is altered in schizophrenia. While early postmortem studies showed a D₂ elevation in schizophrenia (Lee et al. 1978; Seeman et al. 1984), the finding that antipsychotic treatment per se increased striatal D₂ receptor density in experimental animals (Burt et al. 1977; Owen et al. 1980) raised the concern that the D₂ receptor elevation observed in schizophrenia was the consequence of prior drug treatment (Seeman 1987). With the advent of positron emission tomography (PET) and single positron emission computed tomography (SPECT) imaging technologies came the opportunity to investigate D₂ receptor availability in drug-naïve patients in vivo. Initial imaging studies in drug-naïve or drug-free patients remained inconclusive, with some studies reporting higher than normal striatal D₂ receptor density and others showing no difference from controls (Farde et al. 1987; Hietala et al. 1994; Pilowsky et al. 1994; Tune et al. 1993; Wong et al. 1986). Since these initial reports, other studies have followed and failed to detect significant alteration in striatal D₂ receptors in drug-naïve schizophrenic patients (Buchsbaum et al. 2006; Glenthøj et al. 2006; Lomena et al. 2004; Nordstrom et al. 1995; Talvik et al. 2006; Yang et al. 2004). More recently, meta-analyses examining the aggregate results of previous D₂ receptor imaging studies revealed that there is an increase in striatal D₂ receptor density in schizophrenia, although modest (around 13–14 %), that is independent of

the effects of antipsychotic treatment (Kestler et al. 2001; Laruelle 1998; Zakzanis and Hansen 1998). Striatal D₁ receptor density appears unaffected (Abi-Dargham et al. 2002; Karlsson et al. 2002). With the recent availability of high-affinity PET radiotracers, there has been a tremendous interest in investigating extrastriatal dopamine D₂ receptors in schizophrenia. Several PET imaging studies with high-affinity ligands have found consistently lower D₂ receptor densities (in the 20 % range) in the thalamus, as well as in the amygdala, cingulate gyrus, and temporal cortices (Buchsbaum et al. 2006; Kessler et al. 2009; Suhara et al. 2002; Talvik et al. 2003), thus providing no support for a D₂ receptor supersensitivity in schizophrenia. It has been proposed that while there may not be an absolute change in the overall number of D₂ receptors, a higher proportion of D₂ receptors with functional high affinity for DA may explain hyperdopaminergia (Seeman et al. 2005). However, a recent clinical study to investigate levels of those high-affinity state D₂ receptors found no difference between schizophrenia patients and controls (Graff-Guerrero et al. 2009b). Thus, despite extensive efforts over the past 40 years, no convincing evidence has emerged yet that unequivocally points to a D₂ receptor abnormality in schizophrenia.

Dopamine Presynaptic Dysregulation in Schizophrenia

Contrasting with studies looking at postsynaptic D₂ receptors, PET imaging of the presynaptic aspect of DA neurotransmission has provided converging evidence for the existence of presynaptic dopamine overactivity in schizophrenia. In vivo presynaptic DA activity has been investigated using several methods carried out to study particular elements of DA function. The first method involved the use of the DA precursor analog radioligand [¹⁸F]DOPA, whose accumulation in brain represents the activity of the aromatic acid decarboxylase enzyme and the storage capacity of presynaptic DA (Brown et al. 1999) and is generally considered as an index of DA synthesis. The other methods take advantage of the well-described in vivo competing effect exerted by endogenous DA on the binding of some D₂ radiotracers to index evoked DA release or baseline levels of extracellular DA (Ginovart 2005; Laruelle 2000). Without a few exceptions (Dao-Castellana et al. 1997; Elkashef et al. 2000), all studies investigating presynaptic dopamine metabolism indicate a heightened presynaptic capacity of DA synthesis in schizophrenia (Hietala et al. 1995, 1999; Kumakura et al. 2007; Lindstrom et al. 1999; McGowan et al. 2004; Meyer-Lindenberg et al. 2002; Nozaki et al. 2009; Reith et al. 1994) that might be used as an index to discriminate patients from controls (Bose et al. 2008). Interestingly, it has recently been demonstrated that patients with prodromal symptoms of schizophrenia also show elevated striatal DA synthesis (Howes et al. 2009), indicating that presynaptic DA abnormalities predate the onset of illness and are thus likely related to the cause rather than being a consequence of the disorder. Further evidence for an elevated DA availability in schizophrenia comes from studies showing an exaggerated release of DA in the striatum of schizophrenic patients both at basal conditions (Abi-Dargham et al.

2000) and in response to amphetamine (Abi-Dargham et al. 1998; Bertolino et al. 2000; Breier et al. 1997; Laruelle et al. 1996). Taken together, these data suggest that an increased presynaptic capacity of DA synthesis and release may constitute part of the dysfunctional neural connectivity underlying schizophrenia and may be the concurring proximate causes of psychoses. In contrast, a DA hypofunction may prevail in the neocortex (Grace 1991). A reconceptualization of the original DA hypothesis of schizophrenia followed that refined the notion of a global hyperdopaminergia to a cortical/subcortical imbalance of DA tone in brain (Davis et al. 1991; Howes and Kapur 2009). According to this new hypothesis, positive symptoms of the disorder would result from a subcortical hyperdopaminergia, whereas negative symptoms and cognitive deficits would result from a concomitant hypodopaminergia in frontal cortex.

2 Mechanism of Antipsychotic Action

2.1 *Antipsychotic Treatment*

Antipsychotics fall into two classes, typical and atypical, which differ in their side-effect and receptor binding profiles. Typical antipsychotics such as haloperidol and chlorpromazine have been available since the 1950s and belong to the first generation of antipsychotics drugs. Typical antipsychotics are effective in treating both the positive and negative symptoms of schizophrenia, although the degree of improvement of negative symptoms is usually less than that of positive symptoms (Goldberg 1985). Besides their therapeutic efficacy, first-generation agents cause a variety of undesirable adverse events, including acute (parkinsonism, akathisia, dystonia) and later-onset (tardive dyskinesia; TD) extrapyramidal side effects (EPS) and a propensity to cause prolactin elevation. In addition to EPS, typical antipsychotics also cause subjective side effects that are characterized by symptoms of dysphoria/anhedonia, depressed mood, and a slowed mentation (Marder 2005; Voruganti and Awad 2004). These subjective effects can manifest within the first few days of treatment (see reviews in Awad and Voruganti 2005; Lambert et al. 2003) and distinguishing them from the primary negative symptoms of schizophrenia can be difficult (Lewander 1994; Schooler 1994). Subjective distress associated with motor and subjective side effects of typical antipsychotics has a negative impact on patient's quality of life and well-being and can lead to noncompliance (Naber et al. 2005; Robinson et al. 2002), and subsequent relapse (Morken et al. 2008; Robinson et al. 1999). Moreover, the lack of response in 20–40 % of patients with schizophrenia represents another limitation of typical antipsychotic for adequate treatment of the disease (Hellewell 1999).

Atypical (or second-generation) antipsychotics are comparable to typical agents with respect to efficacy in reducing positive symptoms but have been associated with a lower risk to cause EPS (Correll and Schenk 2008; Haro and Salvador-Carulla 2006). However, there are considerable variations in the

propensity of individual atypical agents to cause EPS, with some atypical drugs, such as clozapine and quetiapine, showing no greater EPS than placebo across their full dosage range (Arvanitis and Miller 1997; Goldstein 2000) and some others, such as risperidone and olanzapine, showing increased risk with increased dosage (Lemmens et al. 1999). Studies comparing atypical versus typical agents with respect to EPS risk have commonly used haloperidol, a highly potent typical agent comparator that carries a high liability for EPS, particularly at the relatively high doses used—and not surprisingly in these studies atypicals showed a substantial advantage in terms of EPS. However, large efficacy studies such as CATIE (Rosenheck et al. 2006) and CUtLASS (Jones et al. 2006), which have used moderate doses of midpotency typical antipsychotics such as perphenazine and sulpiride, show that it is possible to get equivalent clinical efficacy with typical antipsychotics at doses that do not confer higher risk for EPS. Thus, while it is generally agreed that atypical antipsychotics have, overall, a more favorable side-effect profile than typical agents, it is uncertain whether this superiority can be sustained when controlling for antipsychotic potency and dose inequities. Similarly, and contrary to common thinking that atypicals have improved efficacy against negative symptoms, meta-analyses revealed rather moderate advantage, if any, of atypical versus typical drugs in the treatment of negative symptoms (Carman et al. 1995; Davis et al. 2003; Leucht et al. 1999, 2009). Several studies even indicate that typical and atypical drugs can be equally effective in this domain (Arvanitis and Miller 1997; Buchanan et al. 1998; Copolov et al. 2000; Leucht et al. 1999; Möller et al. 2008). It has been suggested that the apparent superior efficacy of atypical versus typical drugs may only relate to the relative absence of confounding, secondary negative symptoms with atypical drugs due to use of a high-dose comparator, haloperidol (Kapur and Remington 2001a). Interestingly, the meta-analysis by Leucht et al. (2009) demonstrated that when compared with midpotency typical antipsychotics or moderate doses of haloperidol (7.5 or 12 mg per day), some atypical antipsychotics such as aripiprazole, quetiapine, sertindole, ziprasidone, and zotepine are as effective as typical drugs for treatment of negative symptoms, whereas others such as amisulpride, clozapine, olanzapine, and risperidone are superior. Thus, atypical antipsychotics are a heterogeneous group of drugs with regard to efficacy against negative symptoms, and it remains unclear whether this only reflects a different propensity to induce EPS and dysphoria or a primary efficacy against negative symptoms. Atypical antipsychotics may thus offer only modest efficacy advantages over typical drugs. However, because they are less prone to induce secondary negative symptoms, in terms of EPS and dysphoria, than typical antipsychotics, they are associated with improved subjective experience (Lambert et al. 2011) and compliance to treatment (Haro et al. 2009; Möller et al. 2008) and may thus achieve a better overall prognosis. This advantage must be balanced though with the occurrence of other, nonmotor adverse effects, since some atypicals are associated with a higher risk of prolactin elevation and others with metabolic side effects, such as diabetes, hypercholesterolemia, and weight gain (Luft and Taylor 2006; Newcomer 2005).

2.2 Role of D₂ Receptor Blockade

Besides exhibiting a different side-effect profile, typical and atypical antipsychotics also differ in their receptor binding profiles, with atypical agents acting through a larger spectrum of receptor types, including DA but also serotonergic, cholinergic, and adrenergic receptors. Nevertheless, all antipsychotics share the common ability to antagonize DA D₂ receptors, albeit with different affinities. Early pharmacological studies have established the existence of a close relationship between the clinical potency of antipsychotic drugs and their affinity for D₂ receptors (Creese et al. 1976; Seeman and Lee 1975), pointing to a role of this DA receptor subtype in antipsychotic action. The lack of such correlation for any other DA receptor subtypes (Seeman 1987) further substantiates the view that antipsychotic effects occur primarily through antagonism at D₂ receptors.

Further evidence for this comes from neuroimaging studies in schizophrenia patients that investigated the relationship between antipsychotic-induced D₂ receptor blockade, clinical efficacy, and occurrence of side effects. With a few exceptions, most antipsychotics are effective when 65 % or more of D₂ receptors are blocked in the striatum, indicating that antipsychotic effect is driven primarily by D₂ antagonism (Farde et al. 1992; Kapur et al. 2000a). Increasing striatal D₂ blockade by increasing antipsychotic dosage does not provide additional antipsychotic efficacy but is associated with an increased risk of adverse side effects. Indeed, D₂ blockade exceeding 72 % and 78 % leads to the emergence of hyperprolactinemia and extrapyramidal motor symptoms (EPS), respectively, underscoring the need to carefully control antipsychotic dosage during treatment to avoid adverse effects. These neuroimaging findings have permitted the definition of an optimal therapeutic window of 65–78 % D₂ receptor blockade within which most antipsychotics achieve optimal efficacy with minimal side effects. Although originally demonstrated with the prototypical typical antipsychotic haloperidol, a similar relationship between D₂ receptor blockade and clinical effects was subsequently confirmed for atypical drugs having low EPS liability. Drugs such as remoxipride, olanzapine, and risperidone induce dose-dependent levels of striatal D₂ receptor blockade but achieve therapeutic efficacy only at doses that cross the 65 % threshold level (Kapur et al. 1998, 1999; Nordstrom et al. 1998). However, these drugs dose-dependently lose their low EPS profile because D₂ blockade crossing the 72–75 % level is associated with the emergence of EPS and sustained hyperprolactinemia (Jauss et al. 1998; Knable et al. 1997). Although both the EPS and prolactin elevation are associated with D₂ receptor blockade, different neuroanatomical pathways mediate these effects. Whereas EPS are mediated through excessive blockade of D₂ receptor in striatum, hyperprolactinemia relates to excessive blockade of D₂ receptors in the anterior pituitary, a structure located outside the blood–brain barrier and accessible to drugs that do not penetrate the brain. Atypical antipsychotics vary considerably with regard to their ability to increase prolactin levels (Kapur and Remington 2001a). Drugs such as amisulpride and sulpiride, which display a limited brain penetration, cause few EPS but have a profound effect

on plasma prolactin concentrations when compared to other atypicals such as quetiapine and olanzapine (O'Connor and Brown 1982; Stanniland and Taylor 2000). This dissociation between the occurrence of EPS and prolactin-elevating effect reflects a differential disposition of the drugs across the blood–brain barrier, resulting in higher levels of D₂ receptor blockade in the pituitary than in the striatum (Kapur et al. 2002). Thus, the different propensity of atypical drugs to induce prolactin elevation at therapeutic doses is critically dependent on their ability to cross the brain–blood barrier and the degree to which they induce differential D₂ receptor blockade in the pituitary versus the striatum. Antagonism at the D₂ receptors thus appears central to both the therapeutic and adverse side effects of antipsychotics. Reducing exaggerated DA function through D₂ receptor blockade in the mesolimbic pathway would underlie the progressive resolution of psychosis, whereas excessive reduction of DA function in the nigrostriatal and tuberoinfundibular pathways would lead to EPS and prolactin elevation, respectively. On the other hand, concurrent blockade of D₂ receptors in the mesocortical pathway, where DA function is already deficient in schizophrenia, may even worsen the negative symptoms and cognitive impairment of the disease.

A second approach in the treatment of schizophrenia is to prevent excessive D₂ receptor activation by the use of D₂ partial agonists. Unlike antagonists, which block D₂ activation by endogenous DA, partial agonists activate D₂ receptors but to a lower degree than endogenous DA. The consequence of D₂ partial activation is thus dependent on the local concentration of endogenous DA. When the receptor is hyperactivated by high levels of DA, competitive partial agonist binding to the receptor will have the effect of reducing that activation whereas the opposite effect ensued when the receptor is hypoactivated because of low levels of endogenous DA (Tamminga 2002). Partial DA agonists are therefore believed to restore the cortical/subcortical imbalance of DA tone in schizophrenia by dampening excessive mesolimbic D₂ stimulation and by restoring deficient mesocortical D₂ stimulation (Tamminga 2002). Moreover, by avoiding excessive nigrostriatal D₂ inactivation, a partial D₂ agonist would have a low propensity to cause EPS and prolactin elevation. Aripiprazole, the first successful D₂ partial agonist to come into practice, is effective against both the positive and negative symptoms of schizophrenia (Burris et al. 2002; Kane et al. 2002). At therapeutic doses, aripiprazole occupies 85–95 % of the striatal D₂ receptors without causing the EPS and prolactin elevation commonly associated with such high degrees of D₂ occupancy with antagonists (Gründer et al. 2008; Mamo et al. 2007). With an intrinsic activity of circa 25 %, aripiprazole thus produces levels of D₂ receptor inactivation (i.e., blockade) that ideally fall within the optimal 65–78 % therapeutic window when about 90 % of D₂ receptors are occupied (Mamo et al. 2007). Taken together, studies on the pharmacological action of D₂ antagonists and D₂ partial agonists concur to underline the importance of a fine-tuning of D₂ receptor blockade for achieving optimal antipsychotic benefit and thus further emphasize the central role of this receptor subtype in antipsychotic action.

A few atypical antipsychotics though, namely clozapine and quetiapine, do not fit the conventional window of D₂ receptor blockade suggested for optimal therapeutic response. Clozapine, the prototype of atypical antipsychotic drugs, is

effective in treating patients with refractory schizophrenia (Kane et al. 1988) and, like quetiapine, produces fewer and milder EPS compared to typical antipsychotics and does not induce hyperprolactinemia (Goldstein 1999; Lieberman et al. 1989). Both drugs produce robust antipsychotic effect at less than the conventional 65 % threshold of striatal D₂ receptor blockade (Farde et al. 1989, 1992; Kapur et al. 2000b), suggesting that beyond D₂ receptor blockade in striatum, other receptors or mechanisms also contribute to the therapeutic effect of these drugs. On the other hand, since both clozapine and quetiapine never exceed the 75 % threshold of D₂ blockade, they do not give rise to EPS.

2.2.1 Role of Non-D₂ Receptor Blockade

In the search for the involvement of non-DA D₂ receptor mechanisms in antipsychotic action, the D₃ receptor, which has a high homology with the D₂ receptor but displays a preferential distribution in limbic versus motor regions of the dopaminergic systems, has received special attention. In vitro studies have shown that many antipsychotics display comparable affinity for the D₂ and D₃ receptors (Levant 1997; Schotte et al. 1996). However, the relative contribution of D₃ versus D₂ blockade to antipsychotic efficacy has been difficult to establish due to the lack of selective D₃ receptor radioligands and to the partially overlapping distribution of D₂ and D₃ receptors in brain. The development of [¹¹C](+)-PHNO, a preferring-D₃ receptor agonist, has recently permitted to investigate the impact of stable treatment with antipsychotics on D₃ receptors (Graff-Guerrero et al. 2009a). This neuroimaging study, performed in patients with schizophrenia on long-term treatment (>4 weeks) with olanzapine, clozapine, and risperidone, revealed that while antipsychotics induce high levels of D₂ receptor blockade, they do not block D₃ receptors (Graff-Guerrero et al. 2009a). Thus despite displaying D₃ receptor affinity in vitro, these data suggest either that antipsychotics do not bind D₃ receptor in vivo or that they induce a D₃ receptor upregulation on long-term treatment. Subsequent studies performed in rats and comparing D₂ versus D₃ receptor blockade obtained in vitro and ex vivo indicate that, in contrast to what is obtained in vitro, olanzapine, clozapine, risperidone, and haloperidol selectively block D₂ receptors and have only a marginal effect on D₃ receptors ex vivo (McCormick et al. 2011). Altogether, these studies suggest that at clinically relevant doses, the therapeutic effects of antipsychotic are likely not attributable to D₃ receptor blockade. For additional information and discussion, the reader is referred to Gross and Drescher (2012) in the accompanying volume of the Handbook.

The higher affinity of clozapine for D₄ than for D₂ receptors led to the speculation that the superior clinical profile of this drug was due to D₄ receptor blockade (Van Tol et al. 1991). However, several typical antipsychotic drugs, including haloperidol, have similar affinity for D₂ and D₄ receptors (Roth et al. 1995), whereas several atypical drugs, including quetiapine and amisulpride, have very low D₄ affinity, suggesting that D₄ affinity per se does not confer therapeutic efficacy or low EPS liability. Moreover, several clinical trials with D₄ selective

antagonists failed to show antipsychotic efficacy (Bristow et al. 1997; Corrigan et al. 2004; Kramer et al. 1997).

In addition to having D₂-blocking properties, many atypical antipsychotics are also antagonists at the serotonin 5-HT_{2A} receptor and it has been determined that a high 5-HT_{2A}/D₂ affinity ratio is actually the pharmacological feature that best distinguishes atypical from typical antipsychotics (Meltzer et al. 1989). Antagonism at the serotonin 5-HT_{2A} receptor per se does not mediate antipsychotic activity since subtherapeutic doses of atypical drugs such as risperidone and olanzapine induce nearly complete blockade of 5-HT_{2A} receptor in brain, and become therapeutically effective only at doses that cross the conventional 65 % levels of D₂ receptor blockade (Kapur et al. 1999). A balanced inhibition at the D₂ and 5-HT_{2A} receptors is however thought to be important for the reduced side-effect liability and greater ability of atypical versus typical drugs to improve the negative and cognitive symptoms of schizophrenia (Meltzer 2004; Meltzer et al. 2003). This view is however partly challenged by the high incidence of EPS observed with drugs such as chlorpromazine and loxapine despite high levels of 5-HT_{2A} receptor blockade (Kapur et al. 1997; Trichard et al. 1998) and by the lack of EPS observed with amisulpride despite any action on 5-HT_{2A} receptors (Schoemaker et al. 1997; Trichard et al. 1998). Thus, although 5-HT_{2A} may offer advantages against the negative and cognitive symptoms of schizophrenia, low EPS liability is likely unrelated to 5-HT_{2A} receptor blockade.

Preferential Limbic D₂ Receptor Blockade

The underlying mechanism for clozapine's favorable clinical profile, especially with regard to its low EPS liability, has been the focus of intense research. Apart from being attributed to its multireceptor binding profile, especially its binding at the 5-HT_{2A} receptor, it has been suggested that the reduced EPS liability of clozapine, as well as other atypical antipsychotics, is due to a preferential action in limbic and cortical regions (Strange 2001). Indeed, converging evidence from behavioral (Gardner and Seeger 1983; Ljungberg and Ungerstedt 1985; Oakley et al. 1991), electrophysiological (Chiodo and Bunney 1983; White and Wang 1983), and neurochemical (Lane et al. 1988) studies indicate that, in contrast to classical antipsychotic drugs such as haloperidol, clozapine selectively targets the mesolimbic DA system, while leaving the nigrostriatal system relatively unaffected. For instance, while the acute administration of atypical drugs such as clozapine, quetiapine, sertindole, and olanzapine increases the activity of DA neurons in the VTA but not in the SN, haloperidol activates both subpopulations of DA neurons (Goldstein et al. 1993; Hand et al. 1987; Skarsfeldt and Perregaard 1990; Stockton and Rasmussen 1996). As a consequence, atypical antipsychotics preferentially increase DA output in the nucleus accumbens and prefrontal cortex as compared to the striatum whereas the opposite is observed with haloperidol (Hertel 2006; Moghaddam and Bunney 1990; Youngren et al. 1999). Such a preferential modulation of VTA DA neuronal activity likely contributes to the selective development of

depolarization blockade of VTA DA neurons and consequent selective decrease in mesolimbic DA output seen after chronic clozapine treatment, while both the mesolimbic and nigrostriatal DA systems are equipotently affected by chronic haloperidol (Chiodo and Bunney 1983; Goldstein et al. 1993; Lane et al. 1988; Skarsfeldt 1988; White and Wang 1983). Atypical drug's selectivity for limbic, as opposed to striatal, regions is thought to contribute to the lower incidence of EPS as compared to typical drugs. Accordingly, the "limbic selectivity" hypothesis postulates that atypical antipsychotics induce a preferential blockade of limbic and cortical D₂ receptors, which is associated with clinical efficacy, and a relatively lower striatal D₂ receptor blockade, which is associated with a lower incidence of EPS. However, although some imaging studies indicate that atypical drugs such as clozapine, quetiapine, olanzapine, and risperidone block a higher proportion of temporolimbic than striatal D₂ receptors (Bigliani et al. 2000; Bressan et al. 2003; Kessler et al. 2006; Pilowsky et al. 1997; Stephenson et al. 2000; Vernaleken et al. 2011; Xiberas et al. 2001), other studies fail to do so (Agid et al. 2007; Ito et al. 2009; Kessler et al. 2005; Nyberg et al. 2002; Talvik et al. 2001). Atypical drugs have also been shown to produce equipotent D₂ receptor blockade in the ventral striatum (herein the nucleus accumbens is located) and in the dorsal part of the structure (Kessler et al. 2005, 2006), further calling into question the limbic selectivity theory. Moreover, positive symptom reduction in patients treated with risperidone, olanzapine, or aripiprazole appears to be correlated with striatal rather than cortical or other extrastriatal D₂ receptor blockade (Agid et al. 2007; Kegeles et al. 2008), suggesting that the antipsychotic response may be directly mediated through modulation of striatal rather than cortico-limbic DA activity. Clearly, more clinical investigations are needed to determine the exact role of limbic D₂ receptors in the treatment of schizophrenia.

Transient Versus Continuous D₂ Receptor Blockade

Another aspect of D₂ blockade that has been proposed to be central to atypical antipsychotic action is the between-dose kinetic pattern of receptor blockade achieved during clinical dosing (Kapur and Remington 2001b). In vitro work has demonstrated that while drugs such as haloperidol bind with high affinity and display slow dissociation from D₂ receptors, atypical drugs as a group display faster dissociation rates and are only loosely bound to the receptor (Seeman 2002). Such a rapid dissociation is believed to allow D₂ receptors to be released from the drug and to regain responsiveness relatively quickly during the between-dose interval as surges of dopamine can reaccess the receptors. As opposed to typical drugs with slow receptor dissociation, which produce enduring receptor inactivation, atypical antipsychotics would thus only briefly silence D₂ neurotransmission, thereby allowing antipsychotic action with a lower propensity to induce EPS and sustained hyperprolactinemia. As a consequence, and taking into account plasma half-life of the drug and its active metabolites (Tauscher et al. 2002; Tort et al. 2005), drugs with different receptor dissociation properties may produce different kinetics of D₂ blockade. A number of vivo neuroimaging studies concur

to demonstrate that while clinical dosing with haloperidol gives rise to sustained high levels of D_2 receptor blockade (Baron et al. 1989; Nordstrom et al. 1992), D_2 blockade achieved by clinical dosing with quetiapine is only transiently high and declines rapidly after dose intake to reach undetectable levels at 12–14 h postdosing (Catafau et al. 2008; Gefvert et al. 1998; Kapur et al. 2000b; Tauscher-Wisniewski et al. 2002). The demonstration that transiently high D_2 receptor blockade is sufficient for obtaining and maintaining antipsychotic effect, even in drug-naïve schizophrenic patients, thus called into question the presumed necessity of continuous D_2 receptor blockade to control schizophrenia symptoms (Kapur et al. 2000b). In keeping with a precedent pilot study (Remington et al. 2005), a recent double blind study comparing daily with alternate day (also called “extended”) antipsychotic dosing in stabilized patients over a 6-month trial period supports this idea (Remington et al. 2011). Patients on extended dosing with risperidone or olanzapine did not show any greater risk of relapse or worsening of positive symptoms as compared to those receiving daily dosing, challenging the common presumption that patients need to receive daily dosing to remain stabilized. It is thus possible that transient D_2 blockade is all that is needed to achieve and/or maintain clinical response and that continuous blockade is unnecessary and may even be detrimental to some aspects of patient outcome. Recent preclinical studies provide further support for this view by documenting the effects of transient versus continuous D_2 receptor blockade in animal models predictive of antipsychotic-like efficacy and side-effect liability. Within-day transient D_2 blockade achieved by transient antipsychotic delivery was found to be more effective than continuous D_2 blockade (Samaha et al. 2007, 2008). Moreover, while continuous D_2 blockade resulted in D_2 receptor upregulation and behavioral tolerance (Ginovart et al. 2009; Samaha et al. 2008) and to an increased risk for the development of vacuous chewing movements (i.e., an animal model for tardive dyskinesia) (Turrone et al. 2003), transient D_2 receptor blockade did not. This finding suggests that between-dose transient D_2 blockade may be sufficient to induce antipsychotic response and may even improve therapeutic efficacy by avoiding the development of compensatory and likely counterproductive D_2 supersensitivity that is obtained under conditions of sustained D_2 blockade. Moreover, as the development of behavioral tolerance and D_2 receptor upregulation is thought to correspond, at least partially, to the emergence of tardive dyskinesia (TD) in patients on long-term antipsychotic treatment (Tarsy and Baldessarini 1977), a transient pattern of D_2 blockade might also have a lower incidence of TD. On the other hand, since D_2 blockade falls quickly after dosing, transiency of D_2 blockade may lead to more rapid relapse on sudden discontinuation or missed doses, especially when using drugs with fastest dissociation kinetics such as clozapine and quetiapine. A central question thus remains that is to determine the optimal between-dose interval producing appropriate D_2 blockade transiency to achieve and/or maintain symptom remission with low risk of relapse. This balance may be a challenge because this between-dose interval is likely to be quite variable amongst patients (given the wide interpatient variability in metabolism), but also amongst antipsychotic drugs (given their variable D_2 dissociation properties and half-life of time residency in plasma).

Pharmacokinetic analysis of D₂ blockade however has good heuristic value for exposing processes underlying the various degrees of atypicality seen among antipsychotics and is thus worth further investigation.

3 Mechanisms Underlying Speed and Onset of Antipsychotic Response

One important measure of antipsychotic effectiveness is the time lag between the initiation of antipsychotic treatment and the onset of therapeutic response. It has long been held that time to onset of clinical response is delayed by 2–3 weeks after initiation of treatment. This delayed onset of antipsychotic response is thought to reflect the induction of late-onset phenomena, such as the cessation of midbrain DA neurons firing, also known as depolarization blockade. Indeed, while acute D₂ receptor blockade increases the firing of mesolimbic DA neurons, this initial activation gradually subsides with successive antipsychotic administration and ultimately leads, after 2–3 weeks of chronic treatment, to a reversible cessation of midbrain DA neuron firing. The delayed onset of antipsychotic response is thus thought to correlate with the delayed inactivation of midbrain DA neurons (Grace et al. 1997). Another hypothesis postulates that long-term drug-induced changes in gene expression, protein synthesis, and synaptic remodeling could also mediate the delayed onset of antipsychotic action (Kuhar and Joyce 2001). Given that steady-state levels of D₂ receptor blockade are achieved within 1–2 days of antipsychotic treatment (Nordstrom et al. 1992; Tauscher et al. 2002), the dissociation between rapid effect of antipsychotics on D₂ receptor blockade and their delayed therapeutic efficacy is thus difficult to reconcile with a central role of D₂ blockade in the mechanism of antipsychotic action. However, recent research does not lend support to the “delayed-onset” hypothesis and growing evidence indicates that response to antipsychotic treatment occurs much earlier than originally thought. In a large and pioneering meta-analysis involving nearly 7,500 patients with schizophrenia treated with typical (haloperidol, chlorpromazine) and atypical (risperidone and olanzapine) antipsychotics, Agid et al. (2003, 2006) found that antipsychotics produce discernible clinical improvement within the very first week of treatment and that improvement in psychosis is actually greater in the first week than in each subsequent 3 weeks of treatment. Such an early onset of symptom response has been found to be true for other antipsychotic drugs, including quetiapine (Pae et al. 2007; Small et al. 2004) and amisulpride (Leucht et al. 2005), and to be a reliable marker of subsequent clinical outcome as early nonresponse to antipsychotics strongly predicts subsequent lack of response to continued treatment with the same medication (Correll et al. 2003; Kinon et al. 2008, 2011; Leucht et al. 2005). Further, it has now been demonstrated that robust clinical improvement of psychosis occurs as early as the first 24 h of treatment (Agid et al. 2008; Kapur et al. 2005) and that early improvement is strongly predictive of eventual improvement (Agid et al. 2008; Kinon et al. 2008). In addition to a consistent finding of early

onset of therapeutic benefit, the degree of D₂ receptor blockade measured as early as 48 h after treatment initiation correlates positively with clinical improvement after 2 weeks of treatment (Catafau et al. 2006), thus suggesting that early response is likely to be directly linked to D₂ blockade. Contrary to the common belief that there is delayed onset of antipsychotic benefit, compelling evidence indicates that effective doses of antipsychotics have nearly immediate effects with symptom improvement occurring within the first week of treatment. The fact that discernible clinical effects occur close in time to the almost immediate neuropharmacological action of antipsychotics suggests that antipsychotic efficacy likely results from direct blockade of the D₂ receptors, rather than a purported indirect and delayed downstream effect on DA neuronal pathways.

4 Linking Dopaminergic Disturbances, Psychology and Pharmacology in Schizophrenia

If we accept a causal relationship between dopaminergic disturbances and psychosis, how can we understand the link between such a biological disturbance and the psychological expression of the disease? In other words, how can an excessive DA function in schizophrenia lead to hallucinations and delusions and not to some other manifestations? Moreover, why do full benefits of antipsychotic treatment take several weeks to months whilst steady levels of D₂ receptor blockade and first effects of treatment can be seen as early as after one day of treatment? A model has been proposed (Kapur 2003; Kapur et al. 2005) that links DA to symptom expression, and its blockade to symptom resolution. Inherent to this model is the central role of mesolimbic DA in the neural processing of motivation and reward-based associative learning (Day et al. 2007). Indeed, DA neurons in the mesolimbic system are activated by reward-predicting stimuli, leading to the release of DA in the terminal fields that regulate behavior. Rather than encoding the hedonic value of reward, activation of DA mesolimbic neurons predicts the likelihood of a reward to occur when a reward-related cue is presented (Schultz 2006). In this context, DA released in response to the reward-predicting cue determines its incentive salience and establishes reward-associated memories such that subsequent exposure to the cue can trigger reward-directed behaviors (Berridge 2007). In the case of schizophrenia, it is hypothesized that excessive mesolimbic DA transmission occurs irrespective of the contextual experience and therefore exaggerated salience is attributed to impertinent stimuli and to internal representations (Kapur 2003; Kapur et al. 2005). In support of this hypothesis, increasing evidence obtained in schizophrenia patients indicates an abnormally high physiological response of the ventral striatum to non-reinforced stimuli during reward conditioning, suggesting an abnormal ability to differentiate neutral from motivationally salient stimuli (Diaconescu et al. 2011; Jensen et al. 2008; Murray et al. 2008). Misattribution of motivational salience to irrelevant events translates into distorted thoughts and false perceptions of events that contribute to the formation of delusion as a way for the

patient to provide a rational explanation to abnormal internal and external events and give sense to his/her surrounding world. By blocking mesolimbic DA transmission, antipsychotics would not resolve delusional beliefs per se but would rather dampen aberrant salience such that new experiencing can progressively change the patient's cognitive and emotional experience. Resolution of delusions thus follows a slower course than the immediate antipsychotic-induced dampening of salience because it requires cognitive and psychological work from the patient to overcome the false beliefs. Moreover, since antipsychotics also dampen normal incentive salience, they may contribute to the depressed mood, increased anhedonia, and amotivation associated with treatment, thus explaining some of the undesirable effects of antipsychotics.

5 Conclusion and Future Directions

The last 50 years of research have provided unquestionable evidence for a central role of D₂ receptor blockade in the mechanism of antipsychotic action. The demonstration that therapeutic response is a function of the degree of D₂ blockade and that adequately high levels of D₂ blockade are needed to achieve therapeutic efficacy has constituted key discoveries for our understanding of how antipsychotics work. The complex pharmacology, the different DAergic properties, and differential clinical profiles of atypical versus typical antipsychotic agents have moreover provided useful clues with regard to uncovering the potential mechanisms underlying lower EPS liability. While action at the D₂ receptor remains indispensable for controlling the positive symptoms, sustained D₂ blockade may not be necessary for maintaining antipsychotic response and extended antipsychotic dosing leading to transiently high D₂ blockade may represent an effective strategy to circumvent undesirable side effects associated with continuous dosing. Other key modulators of antipsychotic activity include activity at other receptors, especially at the 5-HT₂ receptor, and are probably required for ameliorating the negative and cognitive symptom domains for which D₂ blockade appears ineffective. Yet, and despite continuous research in the field, the fundamental principle has remained unchanged—D₂ blockade remains necessary and sufficient for the antipsychotic response.

Nevertheless, currently available antipsychotics are not ideal since even atypical drugs, which show benefits in terms of EPS, have an increased risk of weight gain and metabolic disturbances. Additional progress is thus still needed and the search for other pharmacological strategies to treat schizophrenia continues. New treatment approaches to tackle schizophrenia could aim at more directly interrupting the pathophysiological mechanism leading to psychosis rather than just blocking its downstream effect. Indeed, whilst most current antipsychotics are D₂ blockers, no conclusive D₂ abnormalities have yet been identified in schizophrenia and converging evidence indicates that the definitive abnormality contributing to abnormally high DA functioning largely resides presynaptically. Rather than just blocking the downstream effects of inappropriately released DA, new therapeutic strategies

could be directed on upstream factors that control the presynaptic release of DA. One such strategy is currently focused on the use of a glutamate receptor agonist and has provided promising results in patients (Patil et al. 2007), and may thus offer a future alternative to complement or replace the use of D₂ blockers. The pathophysiological mechanisms underpinning a presynaptic DAergic hyperfunction in schizophrenia are however still poorly understood, which limits the rational development of new therapeutics. A better elucidation of those mechanisms will be the challenge of future research on schizophrenia and may provide a rational basis for new pharmacotherapies. The next decade of research will tell whether the DA system has delivered all it can for the treatment of schizophrenia—or whether there are further opportunities to harness it for the benefit of our patients.

References

- Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. *Am J Psychiatry* 155:761–767
- Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000) Increased baseline occupancy of D₂ receptors by dopamine in schizophrenia. *Proc Natl Acad Sci U S A* 97:8104–8109
- Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D₁ receptors and working memory in schizophrenia. *J Neurosci* 22:3708–3719
- Agid O, Kapur S, Arenovich T, Zipursky RB (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. *Arch Gen Psychiatry* 60:1228–1235
- Agid O, Seeman P, Kapur S (2006) The “delayed onset” of antipsychotic action—an idea whose time has come and gone. *J Psychiatry Neurosci* 31:93–100
- Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S (2007) Striatal vs extrastriatal dopamine D₂ receptors in antipsychotic response—a double-blind PET study in schizophrenia. *Neuropsychopharmacology* 32:1209–1215
- Agid O, Kapur S, Warrington L, Loebel A, Siu C (2008) Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. *Schizophr Res* 102:241–248
- Arvanitis LA, Miller BG (1997) Multiple fixed doses of “seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The seroquel trial 13 study group. *Biol Psychiatry* 42:233–246
- Awad AG, Voruganti LN (2005) Neuroleptic dysphoria: revisiting the concept 50 years later. *Acta Psychiatr Scand Suppl* 111(427):6–13
- Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. *Psychopharmacology (Berl)* 99:463–472
- Berridge KC (2007) The debate over dopamine’s role in reward: the case for incentive salience. *Psychopharmacology (Berl)* 191:391–431
- Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, Frank JA, Pickar D, Weinberger DR (2000) The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. *Neuropsychopharmacology* 22:125–132
- Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS (2000) Striatal and temporal cortical D₂/D₃ receptor occupancy by olanzapine

- and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. *Psychopharmacology (Berl)* 150:132–140
- Bose SK, Turkheimer FE, Howes OD, Mehta MA, Cunliffe R, Stokes PR, Grasby PM (2008) Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. *Schizophr Res* 106(2–3):148–155
- Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. *Proc Natl Acad Sci U S A* 94:2569–2574
- Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS (2003) Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. *J Clin Psychopharmacol* 23:5–14
- Bristow LJ, Collinson N, Cook GP, Curtis N, Freedman SB, Kulagowski JJ, Leeson PD, Patel S, Ragan CI, Ridgill M, Saywell KL, Tricklebank MD (1997) L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioural tests. *J Pharmacol Exp Ther* 283:1256–1263
- Brown WD, Taylor MD, Roberts AD, Oakes TR, Schueller MJ, Holden JE, Malischke LM, DeJesus OT, Nickles RJ (1999) FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. *Neurology* 53:1212–1218
- Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. *Am J Psychiatry* 155:751–760
- Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Mukherjee J (2006) D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. *Schizophr Res* 85:232–244
- Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. *J Pharmacol Exp Ther* 302:381–389
- Burt DR, Creese I, Snyder SH (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. *Science* 196:326–328
- Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. *Acta Pharmacol Toxicol* 20:140–144
- Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. *Nature* 180:1200
- Carman J, Peuskens J, Vangeneugden A (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. *Int Clin Psychopharmacol* 10:207–213
- Catafau AM, Corripio I, Perez V, Martin JC, Schotte A, Carrio I, Alvarez E (2006) Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. *Psychiatry Res* 148:175–183
- Catafau AM, Penengo MM, Nucci G, Bullich S, Corripio I, Parellada E, Garcia-Ribera C, Gomeni R, Merlo-Pich E (2008) Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. *J Psychopharmacol* 22:882–894
- Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. *J Neurosci* 3:1607–1619
- Connell PH (1958) Amphetamine psychosis. Oxford University Press, London
- Copolov DL, Link CG, Kowalczyk B (2000) A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'seroquel') and haloperidol in schizophrenia. *Psychol Med* 30:95–105
- Correll CU, Schenk EM (2008) Tardive dyskinesia and new antipsychotics. *Curr Opin Psychiatry* 21:151–156

- Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM (2003) Early prediction of antipsychotic response in schizophrenia. *Am J Psychiatry* 160:2063–2065
- Corrigan MH, Gallen CC, Bonura ML, Merchant KM (2004) Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. *Biol Psychiatry* 55:445–451
- Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. *Science* 192:481–483
- Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot JL (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. *Schizophr Res* 23:167–174
- Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. *Am J Psychiatry* 148:1474–1486
- Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. *Arch Gen Psychiatry* 60:553–564
- Day JJ, Roitman MF, Wightman RM, Carelli RM (2007) Associative learning mediates dynamic shifts in dopamine signaling in the nucleus accumbens. *Nat Neurosci* 10:1020–1028
- Diaconescu AO, Jensen J, Wang H, Willeit M, Menon M, Kapur S, McIntosh AR (2011) Aberrant effective connectivity in schizophrenia patients during appetitive conditioning. *Front Hum Neurosci* 4:239. doi:[10.3389/fnhum.2010.00239](https://doi.org/10.3389/fnhum.2010.00239)
- Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ (2000) 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. *Psychiatry Res* 100:1–11
- Farde L, Wiesel FA, Hall H, Halldin C, Stone-Elander S, Sedvall G (1987) No D2 receptor increase in PET study of schizophrenia. *Arch Gen Psychiatry* 44:671–672
- Farde L, Wiesel FA, Nordstrom AL, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. *Psychopharmacology (Berl)* 99: S28–S31
- Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. *Arch Gen Psychiatry* 49:538–544
- Gardner EL, Seeger TF (1983) Neurobehavioral evidence for mesolimbic specificity of action by clozapine: studies using electrical intracranial self-stimulation. *Biol Psychiatry* 18:1357–1362
- Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R (1998) Time course of central nervous dopamine-D2 and 5-HT₂ receptor blockade and plasma drug concentrations after discontinuation of quetiapine (seroquel) in patients with schizophrenia. *Psychopharmacology (Berl)* 135:119–126
- Ginovart N (2005) Imaging the dopamine system with in vivo [¹¹C]raclopride displacement studies: understanding the true mechanism. *Mol Imaging Biol* 7:45–52
- Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S (2009) D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [¹¹C]-raclopride PET study in cats. *Neuropsychopharmacology* 34:662–671
- Glenthøj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, Friberg L, Baare W, Hemmingsen R, Videbaek C (2006) Frontal dopamine D(2/3) receptor binding in drug-naïve first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. *Biol Psychiatry* 60:621–629
- Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. *Schizophr Bull* 11:453–456
- Goldstein JM (1999) Quetiapine fumarate (seroquel): a new atypical antipsychotic. *Drugs Today (Barc)* 35:193–210
- Goldstein JM (2000) The new generation of antipsychotic drugs: how atypical are they? *Int J Neuropsychopharmacol* 3:339–349
- Goldstein JM, Litwin LC, Sutton EB, Malick JB (1993) Seroquel: electrophysiological profile of a potential atypical antipsychotic. *Psychopharmacology (Berl)* 112:293–298

- Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. *Neuroscience* 41:1–24
- Grace AA, Bunney BS, Moore H, Todd CL (1997) Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. *Trends Neurosci* 20:31–37
- Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, Rusjan P, Houle S, Wilson AA, Kapur S (2009a) The effect of antipsychotics on the high-affinity state of D₂ and D₃ receptors: a positron emission tomography study with [11C]-(+)-PHNO. *Arch Gen Psychiatry* 66:606–615
- Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, Zipursky R, Kapur S (2009b) The dopamine D₂ receptors in high-affinity state and D₃ receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. *Neuropsychopharmacology* 34:1078–1086
- Gross G, Drescher K (2012) The role of dopamine D₃ receptors for antipsychotic activity and cognitive functions. In: Gross G, Geyer M (eds) *Handbook of Experimental Pharmacology*, vol 213. Current Antipsychotics. Springer, Heidelberg
- Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Brocheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rosch F, Schaefer WM, Vernaleken I (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F] fallypride PET study. *Am J Psychiatry* 165(8):988–995
- Hand TH, Hu XT, Wang RY (1987) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. *Brain Res* 415:257–269
- Haro JM, Salvador-Carulla L (2006) The SOHO (schizophrenia outpatient health outcome) study: implications for the treatment of schizophrenia. *CNS Drugs* 20:293–301
- Haro JM, Novick D, Suarez D, Roca M (2009) Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. *J Psychiatr Res* 43(3):265–273
- Hellewell JS (1999) Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. *J Clin Psychiatry* 60(Suppl 23):14–19
- Hertel P (2006) Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. *Synapse* 60:543–552
- Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehtinen V, Ruotsalainen U, Rakkolainen V, Lehtinen V, Wegelius U (1994) Striatal D₂ dopamine receptor characteristics in neuroleptic-naïve schizophrenic patients studied with positron emission tomography. *Arch Gen Psychiatry* 51:116–123
- Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamäki M, Kirvelä O, Ruotsalainen U et al (1995) Presynaptic dopamine function in striatum of neuroleptic-naïve schizophrenic patients. *Lancet* 346:1130–1131
- Hietala J, Syvalahti E, Vilkkumäki H, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamäki M, Eronen E, Ruotsalainen U, Salokangas RK (1999) Depressive symptoms and presynaptic dopamine function in neuroleptic-naïve schizophrenia. *Schizophr Res* 35:41–50
- Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III—the final common pathway. *Schizophr Bull* 35:549–562
- Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. *Arch Gen Psychiatry* 66:13–20
- Ito H, Arakawa R, Takahashi H, Takano H, Okumura M, Otsuka T, Ikoma Y, Shidahara M, Suhara T (2009) No regional difference in dopamine D₂ receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. *Int J Neuropsychopharmacol* 12(5):667–675
- Jauss M, Schroder J, Pantel J, Bachmann S, Gerdson I, Mundt C (1998) Severe akathisia during olanzapine treatment of acute schizophrenia. *Pharmacopsychiatry* 31:146–148

- Jensen J, Willeit M, Zipursky RB, Savina I, Smith AJ, Menon M, Crawley AP, Kapur S (2008) The formation of abnormal associations in schizophrenia: neural and behavioral evidence. *Neuropsychopharmacology* 33:473–479
- Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). *Arch Gen Psychiatry* 63:1079–1087
- Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 45:789–796
- Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. *J Clin Psychiatry* 63:763–771
- Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. *Am J Psychiatry* 160:13–23
- Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. *Prog Neuropsychopharmacol Biol Psychiatry* 27:1081–1090
- Kapur S, Remington G (2001a) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. *Annu Rev Med* 52:503–517
- Kapur S, Remington G (2001b) Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. *Biol Psychiatry* 50:873–883
- Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S (1997) PET evidence that loxapine is an equipotent blocker of 5-HT₂ and D2 receptors: implications for the therapeutics of schizophrenia. *Am J Psychiatry* 154:1525–1529
- Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT₂ and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. *Am J Psychiatry* 155:921–928
- Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT₂ and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. *Am J Psychiatry* 156:286–293
- Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000a) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. *Am J Psychiatry* 157:514–520
- Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000b) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. *Arch Gen Psychiatry* 57:553–559
- Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. *J Pharmacol Exp Ther* 302:1129–1134
- Kapur S, Mizrahi R, Li M (2005) From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis. *Schizophr Res* 79:59–68
- Karlsson P, Farde L, Halldin C, Sedvall G (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naïve patients with schizophrenia. *Am J Psychiatry* 159:761–767
- Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [¹⁸F]fallypride. *Neuropsychopharmacology* 33:3111–3125
- Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2005) Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. *Neuropsychopharmacology* 30:2283–2289

- Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2006) Occupancy of striatal and extrastriatal dopamine D₂ receptors by clozapine and quetiapine. *Neuropsychopharmacology* 31:1991–2001
- Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY (2009) Dopamine D₂ receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. *Biol Psychiatry* 65:1024–1031
- Kestler LP, Walker E, Vega EM (2001) Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. *Behav Pharmacol* 12:355–371
- Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM (2008) Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. *Schizophr Res* 102:230–240
- Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM (2011) Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. *Neuropsychopharmacology* 35(2):581–590. doi:10.1038/npp.2009.164
- Knable MB, Heinz A, Raedler T, Weinberger DR (1997) Extrapyramidal side effects with risperidone and haloperidol at comparable D₂ receptor occupancy levels. *Psychiatry Res* 75:91–101
- Kramer MS, Last B, Getson A, Reines SA (1997) The effects of a selective D₄ dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D₄ dopamine antagonist group. *Arch Gen Psychiatry* 54:567–572
- Kuhar MJ, Joyce AR (2001) Slow onset of CNS drugs: can changes in protein concentration account for the delay? *Trends Pharmacol Sci* 22:450–456
- Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Gründer G (2007) Elevated [18 F]fluorodopamine turnover in brain of patients with schizophrenia: an [18 F]fluorodopa/positron emission tomography study. *J Neurosci* 27:8080–8087
- Lambert M, Schimmelmann BG, Karow A, Naber D (2003) Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. *Pharmacopsychiatry* 36(Suppl 3):S181–S190
- Lambert M, Schimmelmann BG, Schacht A, Suarez D, Haro JM, Novick D, Wagner T, Wehmeier PM, Huber CG, Hundemer HP, Dittmann RW, Naber D (2011) Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models. *J Clin Psychopharmacol* 31:226–230
- Lane RF, Blaha CD, Rivet JM (1988) Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine: involvement of alpha 1-noradrenergic receptors demonstrated by in vivo voltammetry. *Brain Res* 460:398–401
- Laruelle M (1998) Imaging dopamine transmission in schizophrenia. A review and meta-analysis. *Q J Nucl Med* 42:211–221
- Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. *J Cereb Blood Flow Metab* 20:423–451
- Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. *Proc Natl Acad Sci U S A* 93:9235–9240
- Lee T, Seeman P, Tourtellotte WW, Farley JJ, Hornykeiwicz O (1978) Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. *Nature* 274:897–900
- Lemmens P, Brecher M, Van Baelen B (1999) A combined analysis of double-blind studies with risperidone vs. Placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. *Acta Psychiatr Scand* 99:160–170
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared

- to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. *Schizophr Res* 35:51–68
- Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005) Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. *Biol Psychiatry* 57:1543–1549
- Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 373:31–41
- Levant B (1997) The D3 dopamine receptor: neurobiology and potential clinical relevance. *Pharmacol Rev* 49:231–252
- Lewander T (1994) Neuroleptics and the neuroleptic-induced deficit syndrome. *Acta Psychiatr Scand Suppl* 380:8–13
- Lieberman JA, Kane JM, Johns CA (1989) Clozapine: guidelines for clinical management. *J Clin Psychiatry* 50:329–338
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 353:1209–1223
- Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B (1999) Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. *Biol Psychiatry* 46:681–688
- Ljungberg T, Ungerstedt U (1985) A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. *Pharmacol Biochem Behav* 23:479–485
- Lomena F, Catafau AM, Parellada E, Bernardo M, Font M, Gutierrez F, Pavia J (2004) Striatal dopamine D2 receptor density in neuroleptic-naïve and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study. *Psychopharmacology (Berl)* 172:165–169
- Luft B, Taylor D (2006) A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. *Expert Opin Pharmacother* 7:1739–1748
- Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. *Am J Psychiatry* 164:1411–1417
- Marder SR (2005) Subjective experiences on antipsychotic medications: synthesis and conclusions. *Acta Psychiatr Scand Suppl* 111(427):43–46
- McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA (2011) The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. *Neuropsychopharmacology* 35(8):1826–1835. doi:[10.1038/npp.2010.50](https://doi.org/10.1038/npp.2010.50)
- McGowan S, Lawrence AD, Sales T, Quedest D, Grasby P (2004) Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. *Arch Gen Psychiatry* 61:134–142
- Meltzer HY (2004) What's atypical about atypical antipsychotic drugs? *Curr Opin Pharmacol* 4:53–57
- Meltzer HY, Matsubara S, Lee JC (1989) The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. *Psychopharmacol Bull* 25:390–392
- Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 27:1159–1172
- Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF (2002) Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. *Nat Neurosci* 5:267–271
- Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. *J Neurochem* 54:1755–1760
- Möller HJ, Riedel M, Jager M, Wickelmaier F, Maier W, Kuhn KU, Buchkremer G, Heuser I, Klosterkötter J, Gastpar M, Braus DF, Schlosser R, Schneider F, Ohmann C, Riesbeck M, Gaebel W (2008) Short-term treatment with risperidone or haloperidol in first-episode

- schizophrenia: 8-week results of a randomized controlled trial within the German research network on schizophrenia. *Int J Neuropsychopharmacol* 11:985–997
- Morken G, Widen JH, Grawe RW (2008) Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. *BMC Psychiatry* 8:32
- Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G, Jones PB, Bullmore ET, Robbins TW, Fletcher PC (2008) Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. *Mol Psychiatry* 13(239):267–276
- Naber D, Karow A, Lambert M (2005) Subjective well-being under the neuroleptic treatment and its relevance for compliance. *Acta Psychiatr Scand Suppl* 111(427):29–34
- Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. *CNS Drugs* 19(Suppl 1):1–93
- Nordstrom AL, Farde L, Halldin C (1992) Time course of D₂-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. *Psychopharmacology (Berl)* 106:433–438
- Nordstrom AL, Farde L, Eriksson L, Halldin C (1995) No elevated D₂ dopamine receptors in neuroleptic-naïve schizophrenic patients revealed by positron emission tomography and [¹¹C] N-methylspiperone. *Psychiatry Res* 61:67–83
- Nordstrom AL, Nyberg S, Olsson H, Farde L (1998) Positron emission tomography finding of a high striatal D₂ receptor occupancy in olanzapine-treated patients. *Arch Gen Psychiatry* 55:283–284
- Nozaki S, Kato M, Takano H, Ito H, Takahashi H, Arakawa R, Okumura M, Fujimura Y, Matsumoto R, Ota M, Takano A, Otsuka A, Yasuno F, Okubo Y, Kashima H, Suhara T (2009) Regional dopamine synthesis in patients with schizophrenia using L-[beta-¹¹C]DOPA PET. *Schizophr Res* 108:78–84
- Nyberg S, Olsson H, Nilsson U, Maehlum E, Halldin C, Farde L (2002) Low striatal and extra-striatal D₂ receptor occupancy during treatment with the atypical antipsychotic sertindole. *Psychopharmacology (Berl)* 162:37–41
- O'Connor SE, Brown RA (1982) The pharmacology of sulpiride—a dopamine receptor antagonist. *Gen Pharmacol* 13:185–193
- Oakley NR, Hayes AG, Sheehan MJ (1991) Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat. *Psychopharmacology (Berl)* 105:204–208
- Owen F, Cross AJ, Waddington JL, Poulter M, Gamble SJ, Crow TJ (1980) Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration. *Life Sci* 26:55–59
- Pae CU, Kim JJ, Lee CU, Lee SJ, Lee C, Patkar AA, Masand PS, Paik IH (2007) Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. *J Clin Psychiatry* 68:399–405
- Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. *Nat Med* 13:1102–1107
- Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppa T, Harkanen T, Koskinen S, Lonnqvist J (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. *Arch Gen Psychiatry* 64:19–28
- Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW (1994) D₂ dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An I¹²³I-IBZM single photon emission computerised tomography study. *Br J Psychiatry* 164:16–26
- Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997) Limbic selectivity of clozapine. *Lancet* 350:490–491

- Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. *Proc Natl Acad Sci U S A* 91:11651–11654
- Remington G, Seeman P, Shammi C, Mann S, Kapur S (2005) “Extended” antipsychotic dosing: rationale and pilot data. *J Clin Psychopharmacol* 25:611–613
- Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S (2011) “Extended” antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. *J Clin Psychiatry* 72(8):1042–1048. doi:[10.4088/JCP.09m05866yel](https://doi.org/10.4088/JCP.09m05866yel)
- Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koren A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry* 56:241–247
- Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA (2002) Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. *Schizophr Res* 57:209–219
- Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J (2006) Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. *Am J Psychiatry* 163:2080–2089
- Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995) D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. *Psychopharmacology (Berl)* 120:365–368
- Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S (2007) “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. *J Neurosci* 27:2979–2986
- Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S (2008) Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. *Biol Psychiatry* 64:145–152
- Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. *J Pharmacol Exp Ther* 280:83–97
- Schooler NR (1994) Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. *Acta Psychiatr Scand Suppl* 380:21–26
- Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. *Psychopharmacology (Berl)* 124:57–73
- Schultz W (2006) Behavioral theories and the neurophysiology of reward. *Annu Rev Psychol* 57:87–115
- Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. *Synapse* 1:133–152
- Seeman P (2002) Atypical antipsychotics: mechanism of action. *Can J Psychiatry* 47:27–38
- Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. *Science* 188:1217–1219
- Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, Reynolds GP, Tourtellotte WW (1984) Bimodal distribution of dopamine receptor densities in brains of schizophrenics. *Science* 225:728–731
- Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, O’Dowd BF, George SR, Perreault ML, Mannisto PT, Robinson S, Palmiter RD, Talerico T (2005) Dopamine supersensitivity correlates with D2high states, implying many paths to psychosis. *Proc Natl Acad Sci U S A* 102:3513–3518

- Skarsfeldt T (1988) Differential effects after repeated treatment with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopamine neurones in rats. *Life Sci* 42:1037–1044
- Skarsfeldt T, Perregaard J (1990) Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. *Eur J Pharmacol* 182:613–614
- Small JG, Kolar MC, Kellams JJ (2004) Quetiapine in schizophrenia: onset of action within the first week of treatment. *Curr Med Res Opin* 20:1017–1023
- Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. *Drug Saf* 22:195–214
- Stephenson CM, Bigliani V, Jones HM, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Kerwin RW, Pilowsky LS (2000) Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography (SPET) study. *Br J Psychiatry* 177:408–415
- Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. *Neuropsychopharmacology* 14:97–105
- Strange PG (2001) Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. *Pharmacol Rev* 53:119–133
- Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, Halldin C, Farde L (2002) Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. *Arch Gen Psychiatry* 59:25–30
- Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L (2001) No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. *Am J Psychiatry* 158:926–930
- Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L (2003) Decreased thalamic D2/D3 receptor binding in drug-naïve patients with schizophrenia: a PET study with [(11)C]FLB 457. *Int J Neuropsychopharmacol* 6:361–370
- Talvik M, Nordstrom AL, Okubo Y, Olsson H, Borg J, Halldin C, Farde L (2006) Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography. *Psychiatry Res* 148:165–173
- Tamminga CA (2002) Partial dopamine agonists in the treatment of psychosis. *J Neural Transm* 109:411–420
- Tarsy D, Baldessarini RJ (1977) The pathophysiologic basis of tardive dyskinesia. *Biol Psychiatry* 12:431–450
- Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. *Mol Psychiatry* 7:317–321
- Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, Epstein I, Christensen BK, Zipursky RB (2002) Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. *J Clin Psychiatry* 63:992–997
- Tort AB, Souza DO, Lara DR (2005) On the simulation of the time-course of dopamine D2 receptor occupancy from the pharmacokinetics of antipsychotics. *Int J Neuropsychopharmacol* 8:137–139
- Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL (1998) Binding of antipsychotic drugs to cortical 5-HT_{2A} receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. *Am J Psychiatry* 155:505–508
- Tsuang M (2000) Schizophrenia: genes and environment. *Biol Psychiatry* 47:210–220
- Tune LE, Wong DF, Pearlson G, Strauss M, Young T, Shaya EK, Dannals RF, Wilson AA, Ravert HT, Sapp J et al (1993) Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with [(11)C]-N-methylspiperone. *Psychiatry Res* 49:219–237
- Turrone P, Remington G, Kapur S, Nobrega JN (2003) Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. *Neuropsychopharmacology* 28:1433–1439
- van Rossum JM (1966) The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. *Arch Int Pharmacodyn Ther* 160:492–494

- Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. *Nature* 350:610–614
- Vernaleken I, Janouschek H, Raptis M, Hellmann S, Veselinovic T, Brocheler A, Boy C, Cumming P, Hiemke C, Rosch F, Schafer WM, Gründer G (2011) Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. *Int J Neuropsychopharmacol* 13 (7):951–960. doi:[10.1017/S1461145710000374](https://doi.org/10.1017/S1461145710000374)
- Voruganti L, Awad AG (2004) Neuroleptic dysphoria: towards a new synthesis. *Psychopharmacology (Berl)* 171:121–132
- Walker E, Kestler L, Bollini A, Hochman KM (2004) Schizophrenia: etiology and course. *Annu Rev Psychol* 55:401–430
- White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. *Science* 221:1054–1057
- Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JK, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naïve schizophrenics. *Science* 234:1558–1563
- Xiberas X, Martinot JL, Mallet L, Artiges E, Loc HC, Maziere B, Paillere-Martinot ML (2001) Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. *Br J Psychiatry* 179:503–508
- Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH (2004) Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naïve patients with schizophrenia: a dual-isotope SPECT study. *Am J Psychiatry* 161:1496–1498
- Youngren KD, Inglis FM, Pivrotto PJ, Jedema HP, Bradberry CW, Goldman-Rakic PS, Roth RH, Moghaddam B (1999) Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. *Neuropsychopharmacology* 20:403–412
- Zakzanis KK, Hansen KT (1998) Dopamine D2 densities and the schizophrenic brain. *Schizophr Res* 32:201–206



<http://www.springer.com/978-3-642-25760-5>

Current Antipsychotics

Gross, G.; Geyer, M.A. (Eds.)

2012, X, 418 p., Hardcover

ISBN: 978-3-642-25760-5